Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma ; volume:150 ; number:7 ; day:13 ; month:7 ; year:2024 ; pages:1-16 ; date:7.2024
Journal of cancer research and clinical oncology ; 150, Heft 7 (13.7.2024), 1-16, 7.2024
- Creator
-
Sun, Bao-Ye
Zhang, Dai
Gan, Wei
Wu, Jing-Fang
Wang, Zhu-Tao
Sun, Guo-Qiang
Zhou, Jian
Fan, Jia
Yi, Yong
Hu, Bo
Zhang, Bo-Heng
Qiu, Shuang-Jian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-024-05869-1
- URN
-
urn:nbn:de:101:1-2410272135403.354370511494
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sun, Bao-Ye
- Zhang, Dai
- Gan, Wei
- Wu, Jing-Fang
- Wang, Zhu-Tao
- Sun, Guo-Qiang
- Zhou, Jian
- Fan, Jia
- Yi, Yong
- Hu, Bo
- Zhang, Bo-Heng
- Qiu, Shuang-Jian
- SpringerLink (Online service)
Other Objects (12)
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy
Advances in clinical and basic research for hepatocellular carcinoma in China: a 2023 review
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy
Advances in clinical and basic research for hepatocellular carcinoma in China: a 2023 review
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy
Advances in clinical and basic research for hepatocellular carcinoma in China: a 2023 review
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma